All In Biotech

Drug Trial Radar · NCT06937177

Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy

Last checked: Nov 19, 2026Latest source record: Jul 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Apr 28, 2025

Primary completion

Oct 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Endevica BioIndustry
Sponsor type
Industry
First posted
Apr 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled basket trial evaluating mifomelatide (TCMCB07) administered daily by subcutaneous (SC) injection in up to 120 patients. Patients will be enrolled into two cohorts 1) patients with newly diagnosed, advanced, unresectable colorectal cancer (CRC) or 2) patients with newly diagnosed, advanced, unresectable pancreatic ductal adenocarcinoma (PDAC). Within each cohort, patients will be randomized 1:1:1:1 to receive placebo or one of three different doses of mifomelatide (12.5 mg, 25 mg, or 50 mg). This study is designed to evaluate the effects of different doses of mifomelatide on weight, body composition and BMI. The double-blind (DB) phase will generally begin on the first day of the second cycle of first-line cancer chemotherapy and continue for 12-weeks with the goal of maintaining body weight and muscle mass in patients undergoing chemotherapy relative to control. Upon completion of the DB treatment period, eligible patients may enroll in an optional Open Label Extension (OLE) phase and receive mifomelatide SC 25 mg daily for up to an additional 26 weeks. The purpose of the OLE is to further evaluate long-term safety, tolerability and efficacy of mifomelatide.

Conditions

  • Cancer Weight Loss

Interventions

  • TCMCB07Drug

    TCMCB07 is will be provided in single-use vials for subcutaneous administration

  • PlaceboDrug

    Matching placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in body weightTime frame: At 12 weeks of treatment
  2. Incidence and severity of adverse events (AEs), AESIs, and SAEsTime frame: From enrollment to the end of the 12 week dosing period
  3. Incidence of abnormalities in laboratory evaluationsTime frame: From enrollment to the end of the 12 week dosing period
  4. Incidence of abnormalities in vital signsTime frame: From enrollment to the end of the 12 week dosing period

Locations

26 sites in 2 countries. Site status is shown where the registry gives one.

  • Arizona Clinical Research Center

    Tucson, Arizona · Recruiting

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • UCLA Medical Center

    Santa Monica, California · Recruiting

  • Life Clinical Trials

    Coral Springs, Florida · Recruiting

  • Bioresearch Partners

    Hialeah, Florida · Recruiting

  • D&H Cancer Research Center

    Margate, Florida · Recruiting

  • Mt. Sinai Cancer Center

    Miami Beach, Florida · Recruiting

  • BRCR Global

    Tamarac, Florida · Recruiting

  • Piedmont Healthcare Inc.

    Atlanta, Georgia · Recruiting

  • Northwestern University - Robert H. Lurie Comprehensive Cancer Center

    Chicago, Illinois · Not yet recruiting

  • Hope and Healing Cancer Services

    Hinsdale, Illinois · Not yet recruiting

  • Orchard Healthcare Research

    Skokie, Illinois · Recruiting

  • Cancer Centers of Kansas

    Wichita, Kansas · Recruiting

  • Karmanos Cancer Center

    Detroit, Michigan · Recruiting

  • NHO Revive Research Institute

    Lincoln, Nebraska · Recruiting

  • Nebraska Cancer Specialists

    Omaha, Nebraska · Recruiting

  • NYU Langone Health Perlmutter Cancer Center

    New York, New York · Recruiting

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • Hightower Clinical

    Oklahoma City, Oklahoma · Recruiting

  • Medical University of South Carolina

    Charleston, South Carolina · Not yet recruiting

  • Baptist Clinical Research

    Memphis, Tennessee · Recruiting

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee · Not yet recruiting

  • Lumi Research

    Kingwood, Texas · Recruiting

  • Laguna Clinical Research Associates

    Laredo, Texas · Recruiting

  • University of Virginia

    Charlottesville, Virginia · Recruiting

  • Cross Cancer Institute

    Edmonton, Alberta, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.